Hibler Elizabeth A, Molmenti Christine L Sardo, Lance Peter, Jurutka Peter W, Jacobs Elizabeth T
University of Arizona Cancer Center, 1515 N. Campbell Ave, Tucson, AZ, 85724-5024, USA,
Cancer Causes Control. 2014 Jul;25(7):809-17. doi: 10.1007/s10552-014-0382-6. Epub 2014 Apr 16.
Cellular-level studies demonstrate that the availability of the secosteroid hormone 1α,25-dihydroxyvitamin D [1,25(OH)2D] to colon cells promotes anti-carcinogenic activities. Although epidemiological data are relatively sparse, suggestive inverse trends have been reported between circulating 1,25(OH)2D concentration and colorectal neoplasia. We therefore sought to evaluate the relationship between circulating 1,25(OH)2D concentrations and odds for metachronous colorectal adenomas among 1,151 participants from a randomized trial of ursodeoxycholic acid for colorectal adenoma prevention. No relationship between 1,25(OH)2D and overall odds for metachronous lesions was observed, with ORs (95% CIs) of 0.80 (0.60-1.07) and 0.81 (0.60-1.10) for participants in the second and third tertiles, respectively, compared with those in the lowest (p-trend = 0.17). However, a statistically significant inverse association was observed between circulating 1,25(OH)2D concentration and odds of proximal metachronous adenoma, with an OR (95% CI) of 0.71 (0.52-0.98) for individuals in the highest tertile of 1,25(OH)2D compared with those in the lowest (p-trend = 0.04). While there was no relationship overall between 1,25(OH)2D and metachronous distal lesions, there was a significantly reduced odds for women, but not men, in the highest 1,25(OH)2D tertile compared with the lowest (OR 0.53; 95% CI 0.27-1.03; p-trend = 0.05; p-interaction = 0.08). The observed differences in associations with proximal and distal adenomas could indicate that delivery and activity of vitamin D metabolites in different anatomic sites in the colorectum varies, particularly by gender. These results identify novel associations between 1,25(OH)2D and metachronous proximal and distal colorectal adenoma, and suggest that future studies are needed to ascertain potential mechanistic differences in 1,25(OH)2D action in the colorectum.
细胞水平研究表明,结肠细胞可利用的甾体激素1α,25 - 二羟基维生素D [1,25(OH)₂D] 能促进抗癌活性。尽管流行病学数据相对较少,但已有报道称循环中1,25(OH)₂D浓度与结直肠癌之间存在提示性的反向趋势。因此,我们试图在一项关于熊去氧胆酸预防结肠腺瘤的随机试验的1151名参与者中,评估循环中1,25(OH)₂D浓度与异时性结肠腺瘤发生几率之间的关系。未观察到1,25(OH)₂D与异时性病变的总体发生几率之间存在关联,与最低三分位数的参与者相比,第二和第三三分位数参与者的比值比(OR,95%可信区间)分别为0.80(0.60 - 1.07)和0.81(0.60 - 1.10)(p趋势 = 0.17)。然而,观察到循环中1,25(OH)₂D浓度与近端异时性腺瘤的发生几率之间存在统计学显著的反向关联,与最低三分位数的个体相比,1,25(OH)₂D最高三分位数的个体的OR(95%可信区间)为0.71(0.52 - 0.98)(p趋势 = 0.04)。虽然总体上1,25(OH)₂D与异时性远端病变之间没有关系,但与最低三分位数相比,1,25(OH)₂D最高三分位数的女性发生几率显著降低,而男性则不然(OR 0.53;95%可信区间0.27 - 1.03;p趋势 = 0.05;p交互作用 = 0.08)。观察到的与近端和远端腺瘤关联的差异可能表明,维生素D代谢产物在结肠不同解剖部位的递送和活性有所不同,尤其是按性别而异。这些结果确定了1,25(OH)₂D与异时性近端和远端结肠腺瘤之间的新关联,并表明需要进一步研究以确定1,25(OH)₂D在结肠中作用的潜在机制差异。